David Gerber
Co-Director, Simmons Comprehensive Cancer Center Office of Education and Training · UT Southwestern Medical Center
Credentials: · · ·
History
PresentSimmons Comprehensive Cancer Center Office of Education and Training · UT Southwestern Medical Center
- 2007–Present
- Until 2007
- Until 2004
Research
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 7,953 citations
JAMA Oncology · 2018 · 906 citations
The Lancet Oncology · 2017 · 797 citations
49 papers · 43 as a resident
28 papers
23 papers
21 papers
20 papers · 2 as a fellow
15 papers
- JS
15 papers
15 papers
Grants
- 2019–2032
UT Southwestern NCI National Clinical Trials Network LAPS
National Cancer Institute · UG1
Contact PI · $6.4M · Ut Southwestern Medical Center
- 2025–2030
TCR-Antigen Foundation Model to Empower TCR-Based Diagnostics and Therapeutics
National Institute of Allergy and Infectious Diseases · R01
PI · $1M · University of Tx Md Anderson Can Ctr
- 2025–2030
National Cancer Institute · K12
Contact PI · $634.6K · Ut Southwestern Medical Center
- 2020–2025
Finding the Optimal Balance of Immunotherapy Efficacy and Toxicity.
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $3.1M · Ut Southwestern Medical Center
Clinical trials
- 2017–2020
Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System
Principal investigator · Completed
University of Texas Southwestern Medical Center
- 2016–2023
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
Principal investigator · Completed · Phase 1
University of Texas Southwestern Medical Center
- 2013–2016
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
Verastem, Inc.
- 2011–2019
Clinical Trial of ARQ 761 in Advanced Solid Tumors
Principal investigator · Completed · Phase 1
University of Texas Southwestern Medical Center